BR
BRKR.US Bruker Corporation
- Market cap
- USD 9.41B
- P/E
- -
- P/B
- 4.03x
- ROE
- -8.7%
- Dividend yield
- 0.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BRKR.US undervalued?
Graham numberThe Graham number of Bruker Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bruker Corporation fundamental analysis
No fundamental analysis for Bruker Corporation yet.
Bruker Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life scie…
Full company profileBruker Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bruker Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.61B | 1.77B | 1.90B | 2.07B | 1.99B | 2.42B | 2.53B | 2.96B | 3.37B | 3.44B | 3.38B |
| Gross Profit | 743M | 813M | 900M | 995M | 940M | 1.21B | 1.31B | 1.51B | 1.65B | 1.58B | 1.65B |
| Operating Income | 177M | 215M | 262M | 301M | 248M | 413M | 433M | 437M | 253M | 236M | -148M |
| EBITDA | 262M | 300M | 340M | 372M | 321M | 497M | 519M | 676M | 439M | 303M | -19.1M |
| Net Income | 154M | 78.6M | 180M | 197M | 158M | 277M | 297M | 427M | 113M | -8.60M | -199M |
| EPS | 0.95 | 0.49 | 1.14 | 1.26 | 1.02 | 1.81 | 1.99 | 2.90 | 0.76 | -0.06 | -1.31 |
| Balance Sheet | |||||||||||
| Total Assets | 1.81B | 1.95B | 2.13B | 2.77B | 3.05B | 3.65B | 3.61B | 4.25B | 5.81B | 6.24B | 5.83B |
| Total Liabilities | 1.12B | 1.22B | 1.22B | 1.83B | 2.07B | 2.57B | 2.48B | 2.84B | 3.99B | 3.73B | 3.49B |
| Shareholders' Equity | 693M | 734M | 905M | 907M | 961M | 1.07B | 1.11B | 1.38B | 1.78B | 2.46B | 2.29B |
| Cash & Short-term Investments | 500M | 439M | 322M | 685M | 732M | 1.17B | 646M | 488M | 183M | 299M | 167M |
| Total Debt | 412M | 416M | 341M | 881M | 913M | 1.39B | 1.27B | 1.38B | 2.25B | 2.04B | 1.71B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 131M | 154M | 240M | 213M | 333M | 282M | 262M | 350M | 251M | 134M | 149M |
| Capital Expenditure | 37.1M | 43.7M | 49.2M | 73.0M | 98.2M | 92.0M | 119M | 107M | 115M | 120M | 99.3M |
| Free Cash Flow | 93.7M | 111M | 191M | 140M | 235M | 190M | 143M | 243M | 136M | 13.9M | 50.0M |
| Ratios | |||||||||||
| ROE | 22.2% | 10.7% | 19.9% | 21.7% | 16.4% | 25.9% | 26.6% | 31.0% | 6.3% | -0.4% | -8.7% |
| ROA | 8.5% | 4.0% | 8.4% | 7.1% | 5.2% | 7.6% | 8.2% | 10.1% | 1.9% | -0.1% | -3.4% |
| Net Profit Margin | 9.5% | 4.5% | 9.5% | 9.5% | 7.9% | 11.5% | 11.7% | 14.4% | 3.4% | -0.3% | -5.9% |
| Debt to Equity | 0.59x | 0.57x | 0.38x | 0.97x | 0.95x | 1.30x | 1.14x | 1.00x | 1.26x | 0.83x | 0.75x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bruker Corporation dividends
- Dividend yield
- 0.24%
- Forward dividend
- 0.20 USD
- Payout ratio
- -
- Ex-dividend date
- Sep 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 22.8M | 0.15 | - |
| 2024 | USD 30.2M | 0.20 | 26.7% |
| 2023 | USD 29.4M | 0.20 | 6.9% |
| 2022 | USD 29.8M | 0.20 | 10.0% |
| 2021 | USD 24.2M | 0.16 | 8.7% |
| 2020 | USD 24.6M | 0.16 | 15.6% |
| 2019 | USD 25.0M | 0.16 | 12.7% |
| 2018 | USD 25.1M | 0.16 | 14.0% |
| 2017 | USD 25.4M | 0.16 | 32.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bruker Corporation
- Insiders 26.90%
- Institutions 73.10%
- Public & others 0.00%
- Shares outstanding 153M
- Free float 104M
Top funds holding BRKR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4.00M | 2.62% | +0.05% | Oct 2026 |
| Orbis Global Equity Investor | 3.82M | 2.50% | 0.00% | Jun 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.40M | 2.22% | +0.30% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.86M | 1.87% | +0.53% | Sep 2026 |
| Vanguard Small Cap Index | 2.40M | 1.57% | -2.09% | Sep 2026 |
| Fidelity Series Large Cap Stock | 2.36M | 1.54% | 0.00% | Sep 2026 |
| EdRF Big Data N EUR | 1.80M | 1.18% | -0.02% | Sep 2026 |
| First Trust NYSE Arca Biotech ETF | 1.66M | 1.09% | 0.00% | Oct 2026 |
| Orbis SICAV Global Bal Instl Inv | 1.60M | 1.05% | +26.40% | Mar 2026 |
| T. Rowe Price All-Cap Opportunities Fund | 1.59M | 1.04% | -2.19% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 1.56M | 1.02% | +0.35% | Sep 2026 |
| Fidelity Dividend Growth | 1.26M | 0.82% | +1.80% | Sep 2026 |
| Orbis Optimal (US$) Fund | 1.18M | 0.77% | -6.33% | Jun 2026 |
| Franklin Small Cap Value A | 1.14M | 0.75% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 917K | 0.60% | +0.64% | Aug 2026 |
| Fidelity Mid-Cap Stock | 894K | 0.59% | 0.00% | Aug 2026 |
| Fidelity Large Cap Stock | 878K | 0.57% | -0.99% | Sep 2026 |
| iShares Biotechnology ETF | 863K | 0.57% | -0.40% | Oct 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 822K | 0.54% | +1.19% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 806K | 0.53% | +0.92% | Sep 2026 |
Top institutions holding BRKR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 20.2M | 13.25% | +25.68% | Jun 2026 |
| Orbis Allan Gray Ltd | 17.9M | 11.75% | 0.00% | Jun 2026 |
| BlackRock Inc | 11.4M | 7.47% | +2.03% | Jun 2026 |
| Pallas Capital Advisors LLC | 9.48M | 6.21% | +0.02% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.89M | 3.20% | +0.67% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.86M | 3.18% | +0.88% | Jun 2026 |
| OZ Management LLC | 4.63M | 3.03% | +41.44% | Jun 2026 |
| State Street Corp | 4.02M | 2.63% | +2.79% | Jun 2026 |
| Franklin Templeton Inc | 3.23M | 2.11% | +10.62% | Jun 2026 |
| Sachem Head Capital Management LP | 2.92M | 1.91% | 0.00% | Jun 2026 |
| Edmond de Rothschild Holding S.A. | 2.82M | 1.85% | -15.90% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.58M | 1.69% | -1.24% | Sep 2026 |
| AQR Capital Management LLC | 2.51M | 1.65% | +94.35% | Jun 2026 |
| London Company of Virginia | 2.48M | 1.62% | -4.01% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.46M | 1.61% | -0.63% | Jun 2026 |
| Geode Capital Management, LLC | 2.28M | 1.49% | +2.34% | Jun 2026 |
| First Trust Advisors L.P. | 2.07M | 1.35% | +38.37% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.83M | 1.20% | -0.54% | Jun 2026 |
| Artisan Partners Limited Partnership | 1.49M | 0.98% | +4.48% | Jun 2026 |
| Brown Advisory Holdings Inc | 1.44M | 0.95% | -18.89% | Jun 2026 |
Bruker Corporation company profile
- Company name
- Bruker Corporation
- Ticker
- BRKR.US
- Exchange
- USA Stocks
- Listed since
- Aug 4, 2000
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 11,085
- Fiscal year end
- December
- Address
- 40 Manning Road, Billerica, MA, United States, 01821
- Phone
- 978 663 3660
- Website
- bruker.com
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Bruker Corporation management
8- Dr. Frank H. Laukien Ph.D.Chairman, CEO & President · born 1960
- Mr. Gerald N. Herman C.P.A.Executive VP & CFO · born 1958
- Dr. Mark R. Munch Ph.D.Corporate Executive VP & President of Bruker Nano Group · born 1962
- Mr. Juergen W. SregaPresident of Bruker Biosystems Group & Bruker Daltonics Division · born 1955
- Mr. Thomas M. BuresChief Accounting Officer · born 1975
- Mr. J. Brent Alldredge J.D.Senior VP, General Counsel, Secretary & Global Head of Compliance · born 1975
- Dr. Wolfgang Pusch Ph.D.President of Bruker Microbiology & Infection Diagnostics Group
- Dr. Burkhard Prause Ph.D.President and CEO of Bruker Energy & Supercon Technologies, Inc. · born 1967